“Bimekizumab Response Maintenance through Two Years of Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Responded After 16 Weeks: Interim Results from the BE BRIGHT Open-Label Extension Trial”. SKIN The Journal of Cutaneous Medicine, vol. 5, no. 6, Nov. 2021, p. s52, https://doi.org/10.25251/skin.5.supp.52.